William Maichle is an accomplished pharmaceutical industry executive with extensive experience in drug development, mergers & acquisitions, licensing, sales & marketing, and commercial operations. His career includes senior management positions at PharmaNet, and, ProEthic Pharmaceuticals, and Kowa Pharmaceuticals America, Inc. As the COO at ProEthic and Kowa, Mr. Maichle managed the Company’s CNS development pipeline then led the divestment of the Company’s pain franchise for a total value exceeding $50 million. Mr. Maichle also managed ProEthic’s/Kowa’s commercial operations, including expanding Kowa Pharmaceutical America’s commercial operations to over 275 professionals, including a managed markets group, increasing trade relations capabilities, and pharmacovigilance/medical affairs.
In 2010, Mr. Maichle joined Nautlius Neurosciences, Inc, a start-up, private equity backed CNS specialty pharmaceutical company which acquired the ProEthic/Kowa pain franchise. While at Nautilus, Mr. Maichle was responsible for all facets of the business, including the Paragraph IV litigation team, and was named Chief Executive Officer and a Director in April 2011. With only 35 sales representatives, Nautilus grew topline Cambia revenue to over a $25 million run rate by September 2013. On December 17, 2013, Nautilus sold Cambia and related assets to Depomed for a total deal value of $53 million (representing approximately a 3 times multiple of net sales).
Following the sale of Cambia to Depomed and the wind down of Nautilus, Mr. Maichle turned his attention to Kamryn Partners, LLC, a global pharmaceutical industry consulting firm specializing in commercial, drug development, regulatory affairs and transaction advisory services. Kamryn Partners’ clients include several mid-cap specialty pharmaceutical companies, start-up companies, private equity/venture and mezzanine debt providers, and leading investment banks. In May 2015, Mr. Maichle was named President of Tribute Pharmaceuticals US, Inc. (TSX: TRX.V) and continued to serve in that role until the company merged with Pozen Pharmaceuticals (NASDAQ: POZN) to form Aralez Pharmaceuticals, Inc. (NASDAQ: ARLZ).
Mr. Maichle received his BS Degree in Biology with a minor in Chemistry and Psychology from Elizabethtown College. He currently resides in Charlotte, NC.